Neurodegeneration in Autism: A Study of Clusterin, Very Long-Chain Fatty Acids, and Carnitine
- 11 February 2025
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 75 (1) , 1-11
Abstract
The clinical identification of regression phenomena in ASD lacks specific biological or laboratory criteria and is often based on family history and highly subjective observations by clinicians. The present study aimed to investigate the potential role of plasma clusterin (CLU), very long-chain fatty acids (VLCFA), and carnitine as biomarkers of neurodegeneration in children with autism spectrum disorder (ASD) with and without regression. By exploring these biomarkers, we sought to provide insights into mitochondrial dysfunction, glial activation, and lipid metabolism, which may contribute to the pathophysiology of ASD and aid in the early diagnosis and intervention of regression phenomena in ASD. Ninety children aged 2–6 years were included: 30 with autism spectrum disorder (ASD), 30 with regressive ASD, and 30 healthy controls. Psychiatric assessments were conducted using DSM-5 criteria, CARS, ABC, RBS-R, and ASSQ scales. Regression in ASD was evaluated retrospectively using a modified ADI-R questionnaire. Fasting blood samples were collected, and plasma clusterin (CLU), VLCFA, and carnitine levels were measured. Statistical analyses were performed using MANOVA to assess the effect of group differences on dependent biochemical variables. Serum clusterin and carnitine levels showed no significant differences between groups. However, C22 VLCFA levels were significantly higher in both autism groups compared to controls (p = 0.04), with post hoc analysis indicating the difference between the non-regressive and control groups (p = 0.02). Serum carnitine was positively correlated with stereotypic behaviors subscale scores (r = 0.37, p = 0.004) and total scores (r = 0.35, p = 0.006) of RBS-R. Our study provides insights into the complexities of biomarker research in autism spectrum disorder (ASD), highlighting the challenges in identifying consistent biological markers for regression and non-regression phenotypes. Although no significant findings were observed, further biomarker studies are essential to distinguish possible endophenotypes, improve early diagnosis, and uncover potential therapeutic targets in ASD.Keywords
This publication has 49 references indexed in Scilit:
- The chaperone Clusterin in neurodegeneration−friend or foe?BioEssays, 2022
- Prevalence and Age of Onset of Regression in Children with Autism Spectrum Disorder: A Systematic Review and Meta‐analytical UpdateAutism Research, 2021
- Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case–control studyMetabolomics, 2019
- Regression in autism spectrum disorder: Reconciling findings from retrospective and prospective researchAutism Research, 2018
- Brain carnitine deficiency causes nonsyndromic autism with an extreme male bias: A hypothesisBioEssays, 2017
- Regression in Autistic Spectrum DisordersNeuropsychology Review, 2008
- Relative Carnitine Deficiency in AutismJournal of Autism and Developmental Disorders, 2004
- Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with α-synucleinopathiesActa Neuropathologica, 2002
- Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disordersJournal of Autism and Developmental Disorders, 1994
- Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)Journal of Autism and Developmental Disorders, 1980